Browsing by Author "Berna Goker"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    A real-life analysis of patients with rheumatologic\rdiseases on biological treatments: Data from TURKBIO\rRegistry
    (2022) gercek can; Fatos Onen; Dilek Solmaz; YAVUZ PEHLIVAN; Cemal Bes; Sema Yilmaz; Merih Birlik; Sedat Çapar; SONER ŞENEL; Suleyman Serdar Koca; mehmet akif öztürk; Özgül Soysal Gündüz; Ayse Cefle; Servet Akar; Ismail Sari; Ayten Yazici; ABDURRAHMAN TUFAN; SEMINUR HAZNEDAROGLU; Gozde Yildirim-Cetin; Servet Yolbas; Berna Goker; Ediz Dalkılıç; Nurullah Akkoç; Şükran Erten; Nevsun Inanc; Haner Direskeneli; Niels Steen Krogh; Sule Yavuz; Fatih Yıldız; Neslihan Yilmaz
    Objective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey.\rThis study aimed to provide an overview of TURKBIO data collected by June 2018.\rMethods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis\r(AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and\rclinical features, disease activity markers, and other follow-up parameters, current and previous treatments,\rand adverse events were registered electronically at each visit using open-source software. The\rregistration of patient-reported outcome measures was carried out electronically by the patients using\rtouch screens.\rResults: TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588\rpatients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number\rof patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of\rpatients and also visits steadily increased by years. The yearly mean number of visits per patient was\rfound to be 2.3. Significant improvements in disease activity and health assessment parameters were\robserved following the biological treatments. Biologics were often given in combination with a conventional\rsynthetic disease-modifying antirheumatic drug in patients with RA. Infections were the\rmost commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12\rpatients, malignancy in 18, and treatment-related mortality in 31.\rConclusion: TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic\rdiseases in Turkey.
  • No Thumbnail Available
    Item
    The impact of smoking on response to tumor necrosis factor-α inhibitor treatment in patients with ankylosing spondylitis
    (2023) Handan Yarkan Tuğsal; Gokce Kenar; gercek can; Sedat Çapar; Berrin Zengin; Servet Akar; Ediz Dalkılıç; ABDURRAHMAN SONER SENEL; Suleyman Serdar Koca; Berna Goker; Ayten Yazici; Nevsun Inanc; Hülya Ellidokuz; Nurullah Akkoç; Fatos Onen
    Background/aim: To investigate the impact of smoking on disease activity, treatment retention, and response in patients with ankylosing spondylitis (AS) treated with their first tumor necrosis factor-α inhibitor (TNFi). Materials and methods: AS patients who started their first TNFi treatment for the active axial disease (BASDAI ≥ 4) from TURKBIO Registry were included. Treatment response of smoker (current and ex-smokers) and nonsmoker (never smoker) patients were primarily evaluated as achievement of BASDAI50 or improvement in BASDAI at least 20 mm at 3 months and 6 months compared to baseline. Results: There were 322 patients with AS (60% male, 59% smoker, mean age: 38.3 years). The median follow-up time was 2.8 years (Q1– Q3: 1.3–3.8), and disease duration was 3.5 years (Q1–Q3: 0.7–8.2). Smokers had male predominance (p < 0.001), lower ESR (p = 0.03), higher BASDAI (p = 0.02), BASFI (p = 0.05), HAQ-AS (p = 0.007), and ASDAS-CRP (p = 0.04) compared with nonsmokers at baseline. In the multivariate analysis, male gender [OR 2.7 (95%CI 1.4–5), p = 0.002], and concomitant conventional synthetic disease-modifying antirheumatic drug use [OR 2.4 (95%CI 1.1–5.2), p = 0.03] were associated with better treatment response. There was an association of male gender [HR 2.4 (95%CI 1.6–3.7), p < 0.001], older age (≥30years) [HR 1.8 (95%CI 1.1–2.8), p = 0.01], and response to treatment [HR 1.8 (95%CI 1.2–2.9), p = 0.008] with better treatment retention. No impact of smoking status was found on treatment retention and response in univariate and multivariate analyses. Conclusion: This study suggested that smoking was associated with poorer patient-reported outcomes in biologic naïve AS patients initiating their first TNFi treatment, but it had no impact on the TNFi treatment response and retention rate.